Virtuoso-mccarran
SelectiveSeattle, WABiotechnology, Pharmaceuticals, HealthcareLast fund filed October 2019
2 on a current fund
last 24 months
across filed funds
| Vehicle | Filed | Target | Sold to date | Investors |
|---|---|---|---|---|
| Virtuoso-McCarran | October 2019 | $2.8M | $337,500 | 3 |
Amounts are Item 13 as filed: the target is the whole offering, and the amount sold is cumulative across amendments rather than a final close. The filing carries no per-investor amount, so a firm’s own cheque is not recoverable here.
2 partners are named across this firm’s filings, 2 of them on a fund it is deploying now.
| Partner | Activity | Categories | Board seats | Last 24mo |
|---|---|---|---|---|
| Michael Ross | Selective | Biotech & pharma, Digital health, Food & agriculture | 23 | 3 |
Classified sectors of Virtuoso-mccarran’s own portfolio companies, based on 22 with a verified or cited source.
| Firm | Shared boards | Companies |
|---|---|---|
| SV Life Sciences | 23 | 20/20 GeneSystems, AmeriClean Holdings, Andovia, Arsanis, Avitide, CATABASIS PHARMACEUTICALS, CERVILENZ, Deciphera Pharmaceuticals, Dualitas Therapeutics, Euclid Systems, everee, Eyebiotech, FRESCO FOODS, Healthcare Solutions Holdings, Maine Crisp Company, NICE Recovery Systems, Ophthotech, Ribometrix, SUTRO BIOPHARMA, Therini Bio, THESAN PHARMACEUTICALS, TRex Holdings, Xilio Therapeutics |
| 82vs | 2 | Arsanis, Avitide |
| GTP AW | 2 | Arsanis, Avitide |
| Steven Enfield | Quiet | None listed | 0 | 0 |
Activity is filed board seats in the last 24 months: 4+ Active, 2–3 Selective, 1 Slowing, none Quiet. A firm's tier totals its partners, so an active firm may be four partners with one seat each. It undercounts partners who invest without taking a board seat, and filings lag a closing by weeks, so Quiet means the paperwork is quiet, not the person.
Not a filing value: this is Lev’s own classification of each company, one company one vote regardless of how many of Virtuoso-mccarran’s partners are named on its board, shown only when we found a specific, checkable source. Companies with no source read as unclassified and are left out of the shares above.
| Polaris Partners | 2 | Arsanis, TRex Holdings |
| Arboretum Ventures | 1 | CERVILENZ |
| Atlas Venture | 1 | Xilio Therapeutics |
| Bain Capital Life Sciences | 1 | Xilio Therapeutics |
| Borealis | 1 | Avitide |
| Caduceus Capital | 1 | Arsanis |
| Clarus | 1 | CATABASIS PHARMACEUTICALS |
| Hatteras Venture Partners | 1 | Ribometrix |
| Lightstone Singapore | 1 | CATABASIS PHARMACEUTICALS |
| Lightstone Ventures | 1 | CATABASIS PHARMACEUTICALS |
| Mithril | 1 | Avitide |
| Orbimed Asia Partners | 1 | Arsanis |
A shared board seat: a company where filings name a Virtuoso-mccarran partner and a partner at the other firm, both with a clean identity match. Not a claim either firm led or co-led the round, only that both are named on the same board.